Eaton Vance Ohio Municipal Income Trust (EVO)

Halozyme stock rises after withdrawing its €2B acquisition offer for Evotec, while reaffirming strong growth outlook for 2024.

Halozyme offers to acquire Evotec for €11.00 per share, boosting Evotec's value to €2 billion. The merger aims to enhance Halozyme's revenue growth and portfolio.

Evotec sees a 13.3% stock rise amid reports of Triton Partners eyeing a potential buyout after acquiring a 9.99% stake in the company.

Evotec stock is up following progress in its partnership with Bristol Myers Squibb, including a $50 million payment.

Evotec and Novo Nordisk have partnered to develop off-the-shelf cell therapy products. The collaboration will focus on advancing stem cell-based therapies for potential commercialization.

Evotec reports a rise in Q2 sales to $201.12M but posts an EPS loss of $0.54. CEO Christian Wojczewski cites market challenges and outlines cost-cutting measures, including a 7% workforce reduction.

EVO stock results show that Evotec missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.

Pre-market stock movers are a hot topic on Wednesday and we have all of the latest news traders need to know about them this morning!

Evotec consults defense advisers following a significant share price decline, raising concerns about a potential takeover.